TFF Pharmaceuticals Inc (TFFP) Stock Price, Quote, News and Overview
NASDAQ:TFFP - Nasdaq - US87241J2033 - Common Stock
TFFP Quote and Key Statistics
TFF Pharmaceuticals Inc
NASDAQ:TFFP (12/12/2024, 8:00:00 PM)
After market: 0.135 +0.07 (+107.69%)0.065
-0.1 (-60.05%)
TFFP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -261.68% | ||
| ROE | -590.38% | ||
| Debt/Equity | 0 |
TFFP Performance and Technical Analysis
TFFP Ownership and Analysts
TFFP Latest News and Analysis
TFF Pharmaceuticals Announces It Will Wind Down Operations
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has terminated its...
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
Newly published data in the Journal of Drug Delivery Science and Technology demonstrate more uniform drug distribution in the lung compared with other...
TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID
Partnership funded by BARDA and other US government agencies TFF formulation may provide flexibility of delivery and improve storage and distribution...
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to...
About TFFP
Company Profile
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas and currently employs 19 full-time employees. The company went IPO on 2019-10-25. The company is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Company Info
TFF Pharmaceuticals Inc
2600 Via Fortuna Ste 360
Austin TEXAS 78746 US
CEO: Glenn Mattes
Employees: 19
Company Website: https://tffpharma.com/
Investor Relations: https://ir.tffpharma.com/
Phone: 17378021973
TFFP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 73.31 | 707.79B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.5 | 361.50B | ||
| JNJ | JOHNSON & JOHNSON | 14 | 345.13B | ||
| MRK | MERCK & CO. INC. | 16.12 | 242.59B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.87 | 211.14B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.27 | 197.99B | ||
| PFE | PFIZER INC | 10.23 | 149.58B | ||
| SNY | SANOFI-ADR | 12.38 | 129.12B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.51 | 115.12B | ||
| ZTS | ZOETIS INC | 28.94 | 75.20B | ||
| GSK | GSK PLC-SPON ADR | 8.23 | 68.68B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.71 | 41.29B |